ZURA

+ Watchlist + Portfolio

Zura Bio Limited

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.84
52-Week Range: $1.78 – $7.44
Market Cap: $551.02M
P/E (TTM): —
EPS (TTM): -1.12
Dividend Yield: —

Advanced Metrics

Price/Book: 2.78
PEG Ratio: —
Return on Equity: -51.01%
Return on Assets: -31.23%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 12.90
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-48.82M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $354.51M

ZURA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$23.69M	$44.00M	$24.40M	$42.08M
Selling, General & Admin	$3.47M	$18.64M	$30.79M	$33.16M
Operating Expenses	$27.16M	$62.64M	$55.19M	$75.25M
Operating Income	-$27.16M	-$62.64M	-$55.19M	-$75.25M
EBITDA	-$27.16M	-$62.64M	-$55.18M	-$75.20M
Pretax Income	-$27.33M	-$60.56M	-$52.40M	-$68.65M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$25.74M	-$60.36M	-$52.40M	-$68.65M
Diluted EPS	-12.19	-2.09	-0.60	-1.06
Diluted Shares	2.11M	33.06M	75.07M	94.16M

ZURA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.57M	$99.81M	$176.50M	$109.41M
Current Assets	$1.78M	$100.84M	$178.74M	$112.31M
Total Assets	$5.26M	$100.84M	$179.53M	$113.95M
Current Liabilities	$14.82M	$20.30M	$19.51M	$12.41M
Total Debt	$7.76M	—	—	—
Total Liabilities	$27.32M	$21.29M	$19.51M	$12.41M
Retained Earnings	-$32.06M	-$103.49M	-$155.90M	-$224.55M
Shareholders' Equity	-$32.06M	$59.33M	$146.81M	$101.54M
Working Capital	-$13.04M	$80.54M	$159.23M	$99.90M
Net Debt	$6.19M	—	—	—

ZURA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.20M	-$15.05M	-$28.08M	-$64.81M
Capital Expenditure	-$12.00M	-$8.00M	-$5.08M	-$113.00K
Free Cash Flow	-$13.20M	-$23.05M	-$33.15M	-$64.93M
Depreciation & Amortisation	—	$0.00	$9.00K	$49.00K
Stock-Based Compensation	$334.00K	$9.65M	$16.80M	$12.33M
Investing Cash Flow	-$12.00M	-$8.00M	-$5.08M	-$113.00K
Financing Cash Flow	$14.77M	$121.29M	$109.84M	-$2.16M
Net Change in Cash	$1.57M	$98.24M	$76.69M	-$67.09M

ZURA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$10.47M	$8.70M	$11.95M	$10.96M	$14.75M
Selling, General & Admin	$8.78M	$9.36M	$7.57M	$7.46M	$10.75M
Operating Expenses	$19.25M	$18.06M	$19.52M	$18.41M	$25.50M
Operating Income	-$19.25M	-$18.06M	-$19.52M	-$18.41M	-$25.50M
EBITDA	-$19.25M	-$18.05M	-$19.50M	-$18.40M	-$25.48M
Pretax Income	-$17.44M	-$15.99M	-$18.04M	-$17.18M	-$24.22M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$17.44M	-$15.99M	-$18.04M	-$17.18M	-$24.22M
Diluted EPS	-0.19	-0.17	-0.21	—	-0.22
Diluted Shares	92.96M	94.29M	94.56M	—	112.22M

ZURA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$170.57M	$154.49M	$139.02M	$109.41M	$225.59M
Current Assets	$171.69M	$156.99M	$142.29M	$112.31M	$227.00M
Total Assets	$172.50M	$157.81M	$143.94M	$113.95M	$228.64M
Current Liabilities	$21.09M	$18.70M	$25.49M	$12.41M	$11.74M
Total Liabilities	$21.09M	$18.70M	$25.49M	$12.41M	$11.74M
Retained Earnings	-$173.34M	-$189.33M	-$207.37M	-$224.55M	-$248.77M
Shareholders' Equity	$138.20M	$125.91M	$108.24M	$101.54M	$216.90M
Working Capital	$150.60M	$138.29M	$116.80M	$99.90M	$215.26M

ZURA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$11.06M	-$16.03M	-$15.44M	-$22.28M	-$18.92M
Capital Expenditure	-$49.00K	-$15.00K	-$32.00K	-$17.00K	-$13.00K
Free Cash Flow	-$11.11M	-$16.05M	-$15.48M	-$22.30M	-$18.94M
Depreciation & Amortisation	$9.00K	$11.00K	$14.00K	$15.00K	$16.00K
Stock-Based Compensation	$3.64M	$3.73M	$2.38M	$2.58M	$5.01M
Investing Cash Flow	-$49.00K	-$15.00K	-$32.00K	-$17.00K	-$13.00K
Financing Cash Flow	$5.18M	-$34.00K	$3.00K	-$7.32M	$135.12M
Net Change in Cash	-$5.93M	-$16.08M	-$15.47M	-$29.61M	$116.19M

Market Snapshot

About

Zura Bio is a clinical-stage biotechnology company developing novel therapies for immune-mediated diseases. The company focuses on creating differentiated biologic treatments that modulate the immune system to address conditions with significant unmet medical needs. Zura Bio's pipeline includes candidates targeting autoimmune and inflammatory disorders.